Your browser is no longer supported. Please, upgrade your browser.
Settings
DRNA Dicerna Pharmaceuticals, Inc. daily Stock Chart
DRNA [NASD]
Dicerna Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.70 Insider Own8.38% Shs Outstand71.40M Perf Week6.34%
Market Cap1.08B Forward P/E- EPS next Y-1.39 Insider Trans-21.25% Shs Float62.74M Perf Month-1.88%
Income-99.40M PEG- EPS next Q-0.31 Inst Own89.90% Short Float7.58% Perf Quarter9.50%
Sales7.70M P/S140.02 EPS this Y56.40% Inst Trans-1.92% Short Ratio11.86 Perf Half Y35.30%
Book/sh2.63 P/B5.74 EPS next Y-0.70% ROA-37.20% Target Price21.71 Perf Year19.84%
Cash/sh5.20 P/C2.90 EPS next 5Y- ROE-66.10% 52W Range9.31 - 17.98 Perf YTD41.25%
Dividend- P/FCF10.32 EPS past 5Y4.10% ROI-45.00% 52W High-15.68% Beta2.16
Dividend %- Quick Ratio5.00 Sales past 5Y- Gross Margin- 52W Low62.84% ATR0.67
Employees78 Current Ratio5.00 Sales Q/Q106.70% Oper. Margin- RSI (14)58.03 Volatility4.59% 3.97%
OptionableYes Debt/Eq0.00 EPS Q/Q-27.20% Profit Margin- Rel Volume0.30 Prev Close15.10
ShortableYes LT Debt/Eq0.00 EarningsAug 07 AMC Payout- Avg Volume400.89K Price15.16
Recom1.70 SMA200.84% SMA5010.15% SMA20017.63% Volume41,856 Change0.40%
May-24-19Resumed Citigroup Buy $30
Jan-22-19Upgrade Chardan Capital Markets Neutral → Buy $18
Nov-06-18Upgrade B. Riley FBR Neutral → Buy $13.50 → $21
Sep-13-18Initiated Citigroup Buy $27
Aug-15-18Upgrade H.C. Wainwright Neutral → Buy $21
Aug-09-18Reiterated Stifel Buy $18 → $20
Mar-28-18Initiated B. Riley FBR, Inc. Neutral $10
Mar-23-18Downgrade H.C. Wainwright Buy → Neutral $12
Mar-09-18Initiated Chardan Capital Markets Neutral
Feb-05-18Initiated SunTrust Buy $13
Jan-16-18Initiated Evercore ISI Outperform $14
Nov-03-17Reiterated H.C. Wainwright Buy $6 → $10
May-23-17Resumed H.C. Wainwright Buy $5
Apr-10-17Reiterated H.C. Wainwright Buy $8 → $5
Jan-31-17Resumed Leerink Partners Mkt Perform
Dec-12-16Initiated H.C. Wainwright Buy $7
Aug-15-16Reiterated Chardan Capital Markets Neutral $4 → $3.50
Aug-08-16Reiterated Chardan Capital Markets Neutral $4 → $3.50
Jun-30-16Reiterated Stifel Buy $16 → $13
Jun-30-16Reiterated Chardan Capital Markets Neutral $5 → $4
Jul-15-19 07:30AM  Dicerna Receives Breakthrough Therapy Designation for DCR-PHXC for Treatment of Primary Hyperoxaluria Type 1 (PH1) Business Wire
Jul-07-19 11:19AM  5 Stocks With Over 20% Upside Potential, Say Top Analysts TipRanks
Jul-02-19 07:00AM  RNAi startup Dicerna developing new liver drug American City Business Journals -5.32%
07:00AM  Dicerna to Begin Clinical Development of DCR-A1AT for Treatment of Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease Business Wire
Jul-01-19 04:30PM  Dicerna Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jun-21-19 07:30AM  Dicerna Presents Additional Data from PHYOX1 Study of DCR-PHXC in Patients with Primary Hyperoxaluria Type 1 (PH1) and Type 2 (PH2) Business Wire
Jun-20-19 07:30AM  Globally Recognized Nephrologist Joins Dicerna to Support Continued Development of DCR-PHXC for the Treatment of Primary Hyperoxaluria Business Wire
Jun-18-19 11:45AM  Did The Underlying Business Drive Dicerna Pharmaceuticals's (NASDAQ:DRNA) Lovely 393% Share Price Gain? Simply Wall St.
Jun-13-19 07:30AM  Dicerna Hires Industry Veterans to Lead Regulatory Affairs and Patient Advocacy Business Wire
Jun-12-19 04:04PM  Bain's second life sciences fund comes in over $1 billion American City Business Journals +5.63%
Jun-11-19 06:57PM  Heres What Hedge Funds Think About Dicerna Pharmaceuticals Inc (DRNA) Insider Monkey
Jun-04-19 07:30AM  Dicerna Appoints Rob Ciappenelli Chief Commercial Officer Business Wire
Jun-03-19 04:30PM  Dicerna Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
May-28-19 04:05PM  Dicerna to Present at the Jefferies 2019 Healthcare Conference Business Wire
May-16-19 07:30AM  Dicerna Announces Dosing of First Patient in Phase 1 Clinical Trial of DCR-HBVS for the Treatment of Chronic Hepatitis B Virus Business Wire
May-12-19 06:10AM  Edited Transcript of DRNA earnings conference call or presentation 9-May-19 8:30pm GMT Thomson Reuters StreetEvents
May-09-19 09:24PM  Dicerna Pharmaceuticals Inc (DRNA) Q1 2019 Earnings Call Transcript Motley Fool
07:15PM  Dicerna Pharmaceuticals (DRNA) Reports Q1 Loss, Lags Revenue Estimates Zacks
06:07PM  Dicerna Pharmaceuticals: 1Q Earnings Snapshot Associated Press
04:05PM  Dicerna Reports First Quarter 2019 Financial and Operating Results and Provides Corporate Update Business Wire
May-07-19 11:47AM  Hedge Funds Have Never Been More Bullish On Dicerna Pharmaceuticals Inc (DRNA) Insider Monkey -7.13%
May-03-19 04:05PM  Dicerna Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
May-02-19 04:05PM  Dicerna to Report First Quarter 2019 Financial Results and Host Conference Call on May 9, 2019 Business Wire
07:30AM  Dicerna Submits Updated IND Application for DCR-PHXC for Treatment of Primary Hyperoxaluria (PH) for the PHYOX2 Pivotal Trial Business Wire
Apr-16-19 02:39PM  Bain Capital raising another life sciences fund after $720M debut American City Business Journals
Apr-11-19 09:27AM  4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics Zacks
Apr-01-19 04:30PM  Dicerna Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
04:05PM  Dicerna to Present at the H.C. Wainwright Global Life Sciences Conference Business Wire
Mar-29-19 06:30AM  Dicerna Announces the Presentation of Updated Data Demonstrating Utility of its Lead Compound DCR-PHXC in Treating Primary Hyperoxaluria Type 1 (PH1) and Type 2 (PH2) Business Wire
Mar-15-19 05:41AM  Edited Transcript of DRNA earnings conference call or presentation 11-Mar-19 8:30pm GMT Thomson Reuters StreetEvents
Mar-11-19 09:28PM  Dicerna Pharmaceuticals Inc (DRNA) Q4 2018 Earnings Conference Call Transcript Motley Fool +7.41%
05:35PM  Dicerna Pharmaceuticals (DRNA) Reports Q4 Loss, Lags Revenue Estimates Zacks
04:42PM  Dicerna Pharmaceuticals: 4Q Earnings Snapshot Associated Press
04:05PM  Dicerna Reports Fourth Quarter and Year Ended December 31, 2018 Financial Results and Provides Corporate Update Business Wire
02:30PM  Dicerna Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Mar-06-19 08:30AM  New Research: Key Drivers of Growth for Energy Transfer LP, Domo, Accenture, Chevron, Cincinnati Financial, and Dicerna Pharmaceuticals Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire -6.11%
Mar-04-19 04:05PM  Dicerna to Report Fourth Quarter and Year End 2018 Financial Results and Host Conference Call on March 11, 2019 Business Wire
Mar-01-19 04:30PM  Dicerna Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire +5.90%
Feb-22-19 04:49PM  Dicerna Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire
Feb-21-19 09:10AM  ADDING MULTIMEDIA Dicerna Bolsters Leadership Team to Support Continued Growth Business Wire
Feb-12-19 01:17PM  Pioneer in Taking RNA Therpeutics Through the Clinic Joins Skyhawk Therapeutics as Chief Medical Officer PR Newswire
Feb-05-19 07:35AM  Recent Analysis Shows DICK'S Sporting Goods, Zix, Q2, InfraREIT, The Boston Beer, and Dicerna Pharmaceuticals Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Feb-01-19 04:30PM  Dicerna Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Jan-28-19 07:30AM  Dicerna Announces Dosing of First Volunteer in Phase 1 Clinical Trial of DCR-HBVS Designed for the Treatment of Chronic Hepatitis B Virus Business Wire
Jan-24-19 07:30AM  Dicerna Evolves Its Board of Directors to Support Continued Growth Business Wire
Jan-23-19 12:13AM  Edited Transcript of DRNA earnings conference call or presentation 5-Nov-18 9:30pm GMT Thomson Reuters StreetEvents -5.76%
Jan-08-19 04:05PM  Dicerna Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Jan-04-19 07:00AM  Boehringer Ingelheim Exercises Option on Second Hepatic Disease Target from Research Collaboration with Dicerna Business Wire +8.63%
Dec-20-18 07:30AM  Dicerna to Join NASDAQ Biotechnology Index Business Wire
Dec-19-18 07:30AM  Dicerna Announces Closing of Global Licensing and Research Collaboration with Eli Lilly and Company Business Wire
Dec-15-18 11:06PM  Here is What Hedge Funds Think About Dicerna Pharmaceuticals Inc (DRNA) Insider Monkey
Nov-30-18 07:45AM  Analysis: Positioning to Benefit within Dicerna Pharmaceuticals, Sun Life Financial, Autodesk, Eagle Pharmaceuticals, Curis, and Accenture Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Nov-29-18 07:30AM  Dicerna to Participate in Citis 2018 Global Healthcare Conference Business Wire
Nov-28-18 01:05PM  Leerink Starts Coverage Of Genetic Medicine Stocks: 'We See Commercial Execution As Increasingly Driving Returns' Benzinga
Nov-09-18 08:00AM  Dicerna to Highlight Lead GalXC Pipeline Programs, Collaborations, and Advances to GalXC Technology Platform at R&D Day 2018 Business Wire
Nov-06-18 07:30AM  Dicerna to Participate in Upcoming Investor Conferences Business Wire +10.90%
Nov-05-18 06:40PM  Dicerna Pharmaceuticals (DRNA) Reports Q3 Loss, Misses Revenue Estimates Zacks
05:36PM  Dicerna Pharmaceuticals: 3Q Earnings Snapshot Associated Press
04:05PM  Dicerna Reports Third Quarter 2018 Financial and Operating Results and Provides Corporate Update Business Wire
Nov-01-18 09:55AM  3 Pharma Stocks to Make a Portfolio Feel Better Investopedia
Oct-31-18 02:08PM  Biotech Stock Roundup: Celgene, Amgen, Vertex Impress in Q3, DRNA Soars on LLY Deal Zacks
Oct-30-18 07:30AM  Dicerna to Report Third Quarter 2018 Financial Results and Host Conference Call on November 5, 2018 Business Wire
Oct-29-18 09:31AM  Dicerna Soars After Eli Lilly Invests $100M In Licensing, Research Deal Benzinga
07:09AM  Dicerna's stock rockets after licensing, research collaboration with Eli Lilly MarketWatch
06:00AM  Lilly and Dicerna Announce RNAi Licensing and Research Collaboration PR Newswire
06:00AM  Eli Lilly makes bet on gene-silencing drug firm Dicerna Reuters
06:00AM  Drug giant Lilly backs Cambridge's Dicerna in $200M deal American City Business Journals
Oct-25-18 01:00PM  Dicerna Announces Late-Breaking Data Supporting Use of DCR-PHXC in Adults with Primary Hyperoxaluria Types 1 and 2 (PH1 and PH2) Business Wire +7.90%
Oct-24-18 11:28PM  Alexion Pharmaceuticals Inc (ALXN) Q3 2018 Earnings Conference Call Transcript Motley Fool
04:41PM  Big Cap 20 Biotech Stock Dives On Mixed Third-Quarter Revenue Investor's Business Daily
10:46AM  Alexion enters RNA gene-silencing field with $637M Dicerna deal American City Business Journals
07:49AM  Alexion stock rises 3% on Q3 beats, upbeat 2018 guidance MarketWatch
06:30AM  Alexion and Dicerna Announce Collaboration to Discover and Develop RNAi Therapies for Complement-Mediated Diseases Business Wire
Oct-23-18 08:25AM  New Research Coverage Highlights MEDIFAST INC, Palo Alto Networks, Salesforce, Agile Therapeutics, Dicerna Pharmaceuticals, and Corbus Pharmaceuticals Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Oct-05-18 12:54PM  Dicerna Announces Late-Breaking Data from the PHYOX Phase 1 Clinical Trial of DCR-PHXC Will Be Presented at ASN Kidney Week 2018 Business Wire
Sep-24-18 07:30AM  Dicerna to Participate in Two Upcoming Investor Conferences Business Wire +5.50%
Sep-12-18 06:00PM  Bluebird Bio Stock May Have Upside of at Least 60 Percent InvestorPlace
Sep-07-18 02:32PM  Here's Why Dicerna Pharmaceuticals, Inc. Is on a Roller Coaster; Down 18% Yesterday, Up 17% Today Motley Fool +13.75%
11:00AM  3 Stocks to Watch as Immunotherapy Pushes Biotech Growth ACCESSWIRE
07:55AM  The Daily Biotech Pulse: Amgen-AstraZeneca, Boston Scientific Opens Wallet, Advaxis Offering Benzinga
Sep-06-18 10:58PM  Dicerna Announces Pricing of Follow-On Public Offering of Common Stock Business Wire -18.11%
Sep-05-18 04:01PM  Dicerna Announces Proposed Follow-On Public Offering of Common Stock Business Wire
06:05AM  Dicerna Announces Proof of Concept for DCR-PHXC in the Treatment of Primary Hyperoxaluria Business Wire
Aug-29-18 08:10AM  Consolidated Research: 2018 Summary Expectations for Internap, Approach Resources, Agile Therapeutics, Town Sports International, Dicerna Pharmaceuticals, and Cott Fundamental Analysis, Key Performance Indications GlobeNewswire
07:30AM  Dicerna to Participate in Upcoming Investor Conferences Business Wire
Aug-16-18 06:00PM  Dicerna Strengthens Board of Directors with Two New Appointments Business Wire
Aug-14-18 01:30AM  Edited Transcript of DRNA earnings conference call or presentation 8-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Aug-13-18 10:20PM  Alnylam drug approval marks watershed moment for gene-silencing field American City Business Journals
Aug-08-18 07:15PM  Dicerna Pharmaceuticals (DRNA) Reports Q2 Loss, Misses Revenue Estimates Zacks
06:08PM  Dicerna Pharmaceuticals: 2Q Earnings Snapshot Associated Press
04:05PM  Dicerna Reports Second Quarter 2018 Financial and Operating Results and Provides Corporate Update Business Wire
02:30PM  Dicerna Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
10:13AM  Earnings Outlook For Dicerna Pharmaceuticals Benzinga
Aug-01-18 07:30AM  Dicerna to Report Second Quarter 2018 Financial Results and Host Conference Call on August 8, 2018 Business Wire
Jul-25-18 08:20AM  Report: Developing Opportunities within Clearwater Paper, Intercept Pharmaceuticals, Community Trust, Community Bank System, Laboratory Corporation of America, and Dicerna Pharmaceuticals Future Expectations, Projections Moving into 2018 GlobeNewswire
Jul-11-18 07:30AM  Dicerna Receives Recommendation from EMA Committee to Designate DCR-PHXC an Orphan Medicinal Product for the Treatment of Primary Hyperoxaluria (PH) in the EU Business Wire
Jun-19-18 07:30AM  Dicerna Set to Join the Russell 3000® and Russell 2000® Indexes Business Wire
Jun-18-18 07:20AM  Free Daily Technical Summary Reports on Dermira and Three Other Biotech Stocks ACCESSWIRE
May-30-18 07:30AM  Dicerna Doses First Primary Hyperoxaluria Patient with DCR-PHXC in Group B Portion of PHYOX Phase 1 Clinical Trial Business Wire
May-29-18 07:30AM  Dicerna to Present at the Jefferies 2018 Global Healthcare Conference Business Wire
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases. Its principal development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and a program for an undisclosed rare liver disease. The company's development programs also comprise additional rare disease programs; a program for the treatment of hypercholesterolemia; and various programs in various therapeutic areas involving liver function. The company has strategic collaborations with Eli Lilly and Company, Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. Dicerna Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bain Capital Life Sciences InvDirectorMay 29Sale12.501,600,00020,000,0007,330,237May 31 04:15 PM
Weissman James BChief Business OfficerApr 02Option Exercise3.4215,00051,30039,480Apr 04 08:00 PM
Weissman James BChief Business OfficerApr 02Sale15.0015,000225,00024,480Apr 04 08:00 PM
Halak Brian KDirectorNov 06Sale13.19104,3281,376,51319,150Nov 06 04:16 PM
Halak Brian KDirectorNov 05Sale12.9839,901517,91519,922Nov 06 04:16 PM
Halak Brian KDirectorNov 02Sale13.47190,7712,569,68520,217Nov 06 04:16 PM
Halak Brian KDirectorNov 01Sale13.37189,5752,534,61821,629Nov 01 06:08 PM
Halak Brian KDirectorOct 31Sale13.60129,6291,762,95423,037Nov 01 06:08 PM
Halak Brian KDirectorOct 30Sale13.92245,0963,410,61923,996Nov 01 06:08 PM
Weissman James BChief Business OfficerSep 05Option Exercise3.422,3017,86926,781Sep 06 02:21 PM
Weissman James BChief Business OfficerSep 05Sale17.502,30140,26824,480Sep 06 02:21 PM
Weissman James BChief Business OfficerAug 17Option Exercise3.4214,68050,20624,480Aug 20 09:00 PM
LANGER DENNISDirectorAug 15Sale16.0023,810380,96047,978Aug 17 09:00 PM
LANGER DENNISDirectorAug 15Sale16.0014,531232,49629,064Aug 17 09:00 PM